Ультраструктурная реорганизация и стереологический анализ кардиомиоцитов при доксорубициновом повреждении миокарда
Диссертация
Использование антрациклиновых антибиотиков в лечении детей с онкологическими заболеваниями позволило существенно увеличить продолжительность жизни таких пациентов, однако кардиотоксическое действие лечебных препаратов завершалось развитием заболеваний сердечнососудистой системы в отдаленные сроки после завершения лечения (Oeffinger К.С. et al., 2005; Curry H.L. et al., 2006; Franco V.I. et al… Читать ещё >
Список литературы
- Автандилов Г. Г., Яблучанский Н. И., Губенко В. Г. Системная стереометрия в изучении патологического процесса. М.: Медицина, 1981. -192 с.
- Баранов B.C., Баранова Е. В. Генетические аспекты старения // Успехи геронтол. 2007. — Т. 20, № 2. — С. 26 — 34.
- Ватутин Н.Т., Калинкина Н. В., Жданюк Ю. И., Кетинг Е. В. Оценка электрокардиографических изменений при применении антрациклиновых антибиотиков // Укр. кардюл. журн. 1999. — № 5. — С. 48 — 51.
- Ватутин Н.Т., Калинкина Н. В., Кетинг Е. В. Антрациклиновая кар-диомиопатия. Донецк: ДИИИ, 2001. — 236 с.
- Ватутин Н.Т., Калинкина Н. В., Кетинг Е. В. и др. Изменения функционального состояния левого желудочка при воздействии антрациклиновых антибиотиков // Кардиология. 2001. — № 6. — С. 46.
- Гершанович M.JI. Пунанов Ю. А., Сафонова С. А. Профилактика кардиотоксичности антрациклинов в онкопедиатрической практике // Вопросы онкологии. 2006. — № 5. — С.590 — 592.
- Гольдберг Е.Д., Боровская Т. Г., Фомина Т. И. и др. Отдаленные эффекты повреждающего действия антибиотиков антрациклинового ряда на репродуктивную систему крыс // Бюл. экспер. биол. 1996. — Т. 121, № 1. -С. 55−58.
- Дудниченко A.C., Краснопольский Ю. М., Швец В. И. Липосомаль-ные лекарственные препараты в эксперименте и клинике. Харьков: РА-Каравелла, 2001. — 144 с.
- Ефимов В.А., Федюнин С. В., Чахмахчева О. Г. Поперечно-сшитые нуклеиновые кислоты: образование, структура и биологическая роль // Биоорганическая химия. 2010. — Т. 36, № 1. — С. 56 — 80.
- Калинкина Н.В. Патогенез антрациклиновых повреждений сердца // Архив клин, эксперим. мед. 1999. — Т. 8, № 1. — С. 100 — 103.
- Капелькин В.И., Лакомкин В. Л., Цыпленкова В. Г. Функциональные и структурные изменения миокарда в ранней стадии действия адриами-цина // Кардиол. вестн. 2006. — Т. 1, № 2. — С. 14 — 21.
- Луценко C.B., Фельдман Н. Б., Туманов С. Г., Северин С. Е. Молекулярные механизмы противоопухолевой активности антибиотиков антра-циклинового ряда // Вопр. биол. мед. фарм. химии. 2001. — № 2. — С. 3 — 9.
- Лушникова Е.Л., Клинникова М. Г., Молодых О. П., Непомнящих Л. М. Морфологические проявления ремоделированйя сердца при дилатаци-онной кардиомиопатии антрациклинового генеза // Бюл. экспер. биол. -2004. Т. 138, № 12. — С. 684 — 689.
- Лушникова Е.Л., Клинникова М. Г., Молодых О. П., Непомнящих Л. М. Ультраструктурные критерии регенераторно-пластической недостаточности кардиомиоцитов при антрациклиновой кардиомиопатии // Бюл. экспер. биол. 2005. — Т. 139, № 4. — С. 470 — 475.
- Лушникова Е.Л., Непомнящих Л. М., Клинникова М. Г. Морфологическая характеристика ремоделирования миокарда стареющих крыс Ви-стар при компенсаторной гипертрофии // Бюл. экспер. биол. 2001. — Т. 132, № 11.-С. 685−692.
- Лушникова Е.Л., Непомнящих Л. М., Клинникова М. Г., Молодых О. П. Ультраструктурные проявления нарушений регенерации кардиомиоцитов при действии доксорубицина // Морфология. 2005. — № 4. — С. 81 — 84.
- Лушникова Е.Л., Непомнящих Л. М., Розенберг В. Д. Морфологические и молекулярно-генетические основы дилатационной кардиомиопатии. М.: Изд-во РАМН, 2004. — 192 с.
- Лушникова Е.Л., Непомнящих Л. М., Семенов Д. Е. Альтеративная и пластическая недостаточность кардиомиоцитов: Новодриновые повреждения миокарда в условиях антрациклиновой кардиомиопатии // Бюл. экспер. биол. 2001. — Т. 131, № 6. — С. 697 — 702.
- Матяш М.Г., Кравчук Т. Л., Высоцкая В. В. и др. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления // Сиб. онкол. журн. 2008. — № 6. — С. 66−75.
- Непомнящих Л.М. Регенераторно-пластическая недостаточность кардиомиоцитов при нарушении синтеза белков // Бюл. экспер. биол. 2001. -Т. 131, № 1. — С. 11 -21.
- Непомнящих Л.М. Регенераторно-пластическая недостаточностьсердца: Молекулярно-биологические механизмы и морфологические основы // Арх. патол. 2007. — № 1. — С. 3 — 12.
- Непомнящих Л^М., Лушникова Е. Л., Колесникова Л: В. и др. Морфометрический и стереологический анализ миокарда: Тканевая и ультраструктурная организация. Новосибирск, 1984. — 160 с.
- Непомнящих Л. М., Лушникова Е. Л., Ларионов П. М., Шурыгин М. Г. Регенерация миокарда: пролиферативный потенциал кардиомиоцитов и индукция кардиомиогенеза при альтеративной и пластической недостаточности сердца // Вестник РАМН. -2010. № 5. — С. 3 — 11.
- Непомнящих Л.М., Лушникова Е. Л., Непомнящих Г. И. Морфо-метрия и стереология гипертрофии сердца. Новосибирск: Наука, 1986. -304 с.
- Непомнящих Л.М., Лушникова Е. Л., Семенов Д. Е. Регенератор-но-пластическая недостаточность сердца: Морфологические основы и молекулярные механизмы. М.: Изд-во РАМН, 2003. — 255 с.
- Непомнящих Л.М., Лушникова Е. Л., Семенов Д. Е. Ультраструктурные изменения митохондрий в кардиомиоцитах при регенераторно-пластической недостаточности миокарда // Бюл. экспер. биол. 2001. -Т.131, № 2. — С. 218−222.
- Непомнящих Л.М., Лушникова Е. Л., Семенов Д. Е. Ультраструктура ядерного компартмента кардиомиоцитов1 при- регенераторно-пластической недостаточности миокарда // Бюл. экспер. биол. 2000. — Т.130,№ 12.-С. 681−687.
- Непомнящих Л.М., Лушникова Е. Л., Семенов Д. Е. Ультраструктура сократительного аппарата кардиомиоцитов при регенераторно-пластической недостаточности миокарда // Бюл. экспер. биол. 2001. — Т.131, № 3.-С. 347−352.
- Непомнящих Л.М., Лушникова Е. Л., Семенов Д. Е. Паренхима-тозно-стромальные отношения в миокарде: Регенераторно-пластическая недостаточность кардиомиоцитов и развитие диффузного кардиосклероза // Бюл. экспер.биол. 2001. — Т. 132, № 7. — С. 103 — 109.
- Непомнящих Л.М., Молодых H.A., Лушникова Е. Л., Клинникова М. Г., Молодых О. П. Регенераторные реакции миокарда при развитии пластической недостаточности кардиомиоцитов в онтогенезе // Бюл. экспер.биол. 2009. — Т. 148, № 12. — С. 693 — 699.
- Орел Н.Ф. Кардиотоксичность антрациклинов: возможности преодоления // Современная онкология. 2004. — № 3. — С. 121 — 124.
- Победимский Д.Д., Степанов А. Е., Каплун А. П. и др. Разработка технологии производства препарата липодокс — липосомной формы доксо-рубицина // Химия и рынок. 2004. — № 3. — С. 13 — 22.
- Семенова JI.A., Непомнящих JI.M., Семенов Д. Е. Морфология пластической недостаточности мышечных клеток сердца. — Новосибирск: Наука, 1985.-241 с.
- Чернова В.А. Лекарственные и диагностические средства, применяемые в онкологической практике. М.: Медицина, 1982. — 216 с.
- Adams V., Jiang Н., Yu J. et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance // J. Am. Coll. Cardiol. 1999. — Vol. 33. — P. 959 — 965.
- Akimoto H., Bruno N.A., Slate D.L. et al. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes // Cancer Res. 1993. — Vol. 53. — P. 4658 — 4664.
- Albini A., Pennesi G., Donatelli F. at al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention // J. Natl. Cancer. Inst. 2010. — Vol. 102, № 1. — P. 14 — 25.
- Anversa P., Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart // Circ. Res. 1998. — Vol. 83. — P. 1 — 14.
- Arai M., Tomaru K., Takizawa T. et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits // J. Mol. Cell. Cardiol. 1998. — Vol. 30, № 2. — P.243 — 254.
- Arai M., Yoguchi A., Takizawa T. et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2±ATPase gene transcription // Circ. Res. 2000. — Vol. 86. — P. 8 — 14.
- Arcamone F., Cassinelli G., Fantini G. et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius // Biotechnol. Bioeng. 1969. — Vol. 11.-P. 1101 — 1110.
- Arola O J., Saraste A., Pulkki K. et al. Acute doxorubicin cardiotoxi-city involves cardiomiocyte apoptosis // Cancer Res. 2000. — Vol.60- - P. 1789 -1792.
- Asmis R., Qiao M., Rossi R.R. et al. Adriamycin promotes macrophage dysfunction in mice // Free Radic. Biol. Med. 2006. — Vol. 41(1). — P. 165−174.
- Asmis R., Wang Y., Xu L. et al. A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages // FASEB J. -2005.- Vol. 19 (13).-P. 1866−1868.
- Aubel-Sadron G., Londos-Gagliardi D. Daunorubicin and doxorubicin,. anthracycline antibiotics, a physicochemical and biological review // Biochimie. -1984. Vol. 66, №N 5. — P. 333 — 352.
- Bachur N.R. Adriamycin-daunomycin cellular pharmacodynamics // Biochem. Pharmacol. 1974. — Suppl. 2. — P. 207 — 216.
- Bachur N.R., Riggs C.E., Green M.R. et al. Plasma Adriamycin and daunorubicin levels by fluorescence and radioimmunoassay // Clin. Pharmacol. Ther. 1977. — Vol. 21. — P. 70 — 77.
- Balducci L., Extermann M. Management of cancer in the older person: a practical approach // Oncologist. 2000. — Vol. 5. — P. 224 — 237.
- Balducci L., Yates J. General guidelines for management of older patients with cancer // Oncology. 2000. — Vol. 14. — P. 221 — 227.
- Beltrami A.P., Barlucchi L., Torella D. et al. Adult cardiac stem cells are multipotent and support myocardial regeneration // Cell. 2003. — Vol. 114.-P. 763 — 776.
- Benjamin R.S. Clinical pharmacology of Adriamycin (NSC-123 127) // Cancer Chemother. Rep. 1975. — Vol. 6. — P. 183 — 185.
- Benjamin R.S., Riggs C.E., Bachur N.R. Pharmacokinetics and metabolism of adriamycin in man // Clin Pharmacol. Ther. 1973. — Vol. 14. — P. 592−600.
- Besse S., Assayag P., Delcayre C. et al. Normal and hypertrophied senescent rat heart: mechanical and molecular characteristics // Am. J. Physiol. -1993. Vol. 265, Pt. 2. — P. H183 — 190.
- Billingham M-E., Mason J.W., Bristow M.R., Daniels J.R. Anthracy-cline cardiomyopathy monitored by morphological changes // Cancer Treat. Rep. 1978. — Vol. 62. — P. 865 — 872.
- Blum R.H. An overview of studies with adriamycin (NSC-123 127) in the United States // Cancer Chemother. Rep. 1975. — Vol. 6, Pt. 3. — P. 247 -251.
- Bonadonna G., Beretta G., Tancini G. et al. Adriamycin studies at the Instituto Nazionale Tumori, Milan // Cancer Chemother. Rep. 1975. — Vol. 6. -P. 231−245.
- Bonadonna G., Zambetti M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three, positive lymph nodes. Ten-year results // JAMA. 1995. — Vol. 273. — P. 542 — 547.
- Bottone A.E., De Beer E.L., Voest E.E. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system // J. Mol. Cell. Cardiol. 1997. — Vol. 29. — P. 1001 — 1008.
- Bottone A.E., Voest E.E., De Beer E.L. Impairment of the actin-myosin interaction in permeabilized cardiac trabecular after chronic doxorubicin treatment // Clin Cancer Res. 1998. — Vol. 4. — P. 1031 — 1037.
- Boucek R.J., Buck S.H., Scott F. et al. Anthracycline-induced tension in permeabilized cardiac fibers: evidence for the activation of the calcium release channel of sarcoplasmic reticulum // J. Mol. Cell. Cardiol. 1993. — Vol. 25. — P.249.259.
- Boucek R.J., Dodd D.A., Atkinson J.B. et al. Contractile failure in chronic doxorubicin-induced cardiomyopathy // J. Mol. Cell. Cardiol. 1997. -Vol. 29.- P. 2631 -2640.
- Breed J.G., Zimmermann A.N., Dormans J.A., Pinedo H.M. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit // Cancer Res. 1980. — Vol. 40. — P. 2033 — 2038.
- Bristow M.R. Anthracycline cardiotoxicity // Drug-induced heart desease / M.R.Bristow, ed. -N.Y.: Elsevier, 1980. P. 191 — 215.
- Bristow M.R. Toxic cardiomyopathy due to doxorubicin // Hosp. Pract.- 1982.-Vol. 17.-P. 101−108.
- Burgess D.H., Svensson M., Dandrea T. etal. Human skeletal muscle cytosols are refractory to cytochrome c-dependent activation of type-II caspases and lack APAF-1 // Cell. Death. Differ. 1999. — Vol. 6(3). -P. 256 — 261.
- Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity // Prog. Cardiovasc. Dis. 2010. — Vol. 53, № 2. — P. 121 -129.
- Cardinale D., Sandri M.T., Colombo A. et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy // Circulation. 2004. — Vol. 109, № 22. — P. 2749 — 2754.
- Caroni P., Villani F., Carafoli E. The cardiotoxic antibiotic doxorubicin^ inhibits the Na+/Ca2+ exchanger of dog heart sarcolemmal vesicles // FEBS Lett. 1981. -Vol. 130.-P. 184 — 186-
- Carre F., Rannou F., Sainte Beuve C. et al. Arrhythmogenicity of the hypertrophied and senescent heart and relationship to membrane proteins involved in the altered calcium handling // Cardiovasc. Res. — 19 931 Vol. 27. — P. 1784 -1789-
- Chan K.K., Cohen J.L., Gross J.F. etal. Prediction of adriamycin disposition in cancer patient using a physiologic, pharmacokinetic model // Cancer Treat. Rep. 1978. — Vol. 62, № 8. — P. 1161 — 1171,
- Chen S., Garami M., Gardner D.G. Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes // Hypertension. 1999. — Vol. 34. — P. 1223 — 1231.
- Chen Y., Saari J.T., Kang Y.J. Weak antioxidant defenses make theheart a target for damage in copper-deficient rats // Free Radic. Biol. Med. 1994. -Vol. 17.-P. 529−536.
- Chlebowski R.T. Adriamycin (doxorubicin) cardiotoxicity: a rewiew // West J. Med. 1979. — Vol. 131, № 5. — P. 364 — 368.
- Collins I., Weber A., Levrns D. Transcriptional consequences of topoisomerase inhibition // Mol. Cell. Biol. 2001. Vol. 21. — P. 8437 — 8451.
- Creutzig U., Diekamp S., Zimmermann M., Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML // Pediatr. Blood Cancer. 2006. — Vol. 43. — P. 12.
- Cruz-Orive L.M., Weibel E.R. Recent stereological methods for cell biology: a brief survey // Am. J. Physiol. 1990. — Vol. 258, N 4 (Pt 1). — P. 148 -156.
- Curigliano G., Mayer E.L., Burstein H.J. et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review // Prog. Cardiovasc. Dis. -2010. Vol. 53, № 2. — P. 94 — 104.
- Curry H.L., Parkes S.E., Powell J.E., Mann J.R. Caring for survivors of childhood cancers: the size of the problem // Eur. J. Cancer. — 2006.* — Vol. 42, № 4.-P. 501−508.
- Cusack B.J., Mushlin P. S., Johnson C.J., Vestal R.E., Olson R.D. Aging increases the cardiotoxicity of daunorubicin and daunorubicinol in the rat // J. Gerontol. A Biol. Sci. Med. Sci. 1996. — Vol. 51, № 5. — P. 376 — 384.
- Cusack B.J., Musser B., Gambliel H., Hadjokas N.E., Olson R.D. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats // Cancer. Chemother. Pharmacol. 2003. — Vol. 51(2). — P. 139 — 146.
- Cusack B.J., Young S.P., Gabliel H., Olson R.D. Effect of aging on cardiac contractility in a rat model of chronic daunorubicin cardiotoxicity // Cardiovasc. Toxicol. 2002. — Vol. 2, N 2. — P. 99 — 109.
- Cusack B.J., Young S.P., Vestal R.E., Olson R.D. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat // Cancer Chem. Pharmacol. 1997. — Vol.39,№ 6.-P. 505−512.
- Danz E.D., Skramsted J., Henry N. et al. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirtl pathway // Free. Radic. Biol. Med. 2009. — Vol. 46, № 12: — P. 1589 — 1597.
- Daosukho C., Chen Y., Noel T. et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against adriamycin-induced cardiac injury // Free. Radic. Biol. Med. 2007. — Vol. 42, № 12. — P.1818 — 1825.
- Daosukho C., Ittarat W., Lin S.M., Induction of manganese superoxide dismutase (MnSOD) mediates cardioprotective effect of tamoxifen (TAM) // J. Mol. Cell Cardiol. 2005. — Vol. 39, № 5. — P.792 — 803.
- De Beer E.L., Bottone A.E., van der Velde J., Voest E.E. Doxorubicin impairs crossbridge turnover in skinned trabeculae after acute and chronic treatment // Mol. Pharmacol. 2000. — Vol. 57. — P. 1152 — 1157.
- De Beer E.L., Bottone A.E., Voest E.E. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: A rewiew // Eur. J. Pharmacol. 2001. — Vol. 415. — P. 1 — 11.
- De Beer E.L., Finkle H., Voest E.E., Van Hejst B.G.V., Schiereck P. Doxorubicin interacts directly with skinned single skeletal muscle fibers // Eur. J. Pharmacol. 1992. — Vol. 214. — P. 97 — 100.
- Di Fronzo G., Lenaz L., Bonadonna G. Distribution and excretion of a adriamycin in man//Biomedicine. 1973.-Vol. 19.-P. 169−171.
- DiMarco A., Gaetani M., Scarpinato B. Adriamycin (NSC-123 127): A new antibiotic with antitumor activity // Cancer Chemother. Rep. Part 1. 1969. -Vol. 53.-P. 33−37.
- Dolci A., Dominici R., Cardinale D. et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use // Am. J. Clin. Pathol. 2008. — Vol. 130, № 5.-P. 688 -695.
- Doroshow J.H. Doxorubicin-induced cardiac toxicity // N. Engl. J. Med. 1991. — Vol. 324. — P. 843 — 845.
- Dranitsaris G., Rayson D., Vincent M. et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines // Breast Cancer Res. Treat. 2008. — Vol. 107, № 3*.-P. 443−450.
- Drummond R.M., Fay F.S. Mitochondria contribute to Ca2+ removal in smooth muscle cells // Eur. J. Physiol. 1996. — Vol. 431. — P. 473 — 482.
- Dudka J., Burdan F., Korga A. et al. The diagnosis of anthracycline-induced cardiac damage and heart failure // Postery Hig. Med. Dosw. 2009. -Vol. 63.-P. 225−233.
- Duquaine D., Hirsch G.A., Chakrabarti A. et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase // Vase. Med. 2003. — Vol. 8(2). P. 101 — 107.
- Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines // Semin. Oncol. 2006. — Vol. 33, Suppl. 8. — S. 2 — 7.
- Ewer M.S., Ewer S.M. Long-term cardiac safety of dose-dense an-thracycline therapy cannot be predicted from early ejection fraction data // J. Clin. Oncol 2009. — Vol. 27, № 36. — P.6073 — 6075.
- Ewer M.S., Martin F.J., Henderson C. et al. Cardiac safety of liposomal anthracyclines // Semin. Oncol. 2004. — Vol. 31, № 6. — P. 161 — 181.
- Ferrans V.J., Clark J.R., Zhang J. et al. Pathogenesis and prevention of doxorubicin cardiomyopathy // Tsitologiia. 1997. — Vol. 39, № 10. — P.928 -937.
- Franco V.I., Henkel J.M., Miller T.L., Lipshultz S.E. Cardiovascular effects in childhood cancer survivors treated with anthracyclines // Cardiol. Res. Pract. 2011. — Vol. 2011. — P. 134 679.
- Fu X.Q., Yu J.P. Luo H.S., Yu H.G. The expression and role of PTEN in doxorubicin induced gastric cancer cell apoptosis // Zhonghua. Nei. Ke. Za. Zhi. 2010- - Vol. 49, № 5. — P.422 — 425.
- Fujita K., Shinpo K., Yamada K. et al. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs // Cancer Res. — 1982. — Vol. 42. P. 309−316.
- Fukuda F., Kitada M., Horie T., Awazu S. Fluorescent substances and high molecular weight protein aggregates formed in rat heart mitochondria upon doxorubicin-induced lipid peroxidation // J. Pharm. Pharmacol. 1995. — Vol.47(3).-P. 246−249.
- Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin // Biochem. Pharmacol. 1999. — Vol. 57, № 7. — P. 727 — 741.
- Gille L., Nohl H. Analyses of the molecular mechanism of Adriamy-cin-induced cardiotoxicity // Free Radic. Biol. Med. 1997. — Vol. 23, № 5. — P. 775−782.
- Goldberg A.L. ATP-dependent proteases in prokaryotic and eukaryot-ic cells // Semin. Cell Biol. 1990. — Vol. 1. — P. 423 — 432.
- Graham E., Rodwell J., Sonu R. et al. The transcriptional profile of aging in the human kidney // PLOSBiology. 2004. — Vol. 2, № 12. — P. 1 — 23.
- Gunz W.I., Sridhar K.S., Ganz S.S. et al. Rewiew of tests for monitoring doxorubicin-induced cardiomyopathy // Oncology. 1996. — Vol. 53. — P. 461 -470.
- Goormaghtigh E., Ruysschaert J.M. Anthracycline glycoside-membrane interactions // Biochim. Biophys. Acta. 1984. — Vol. 779. — P. 271 -288.
- Hardouin S., Mansier P., Bertin B. et al. beta-Adrenergic and muscarinic receptor expression are regulated in opposite ways during senescence in rat left ventricle // J. Mol. Cell. Cardiol. 1997. — Vol. 29. — P. 309 — 319.
- Harrison DiT., Sanders L.A. Pericarditis in a case of early daunorubicin cardiomyopathy // Ann. Intern. Med. 1976. — Vol. 85. — P. 339 — 341.
- Hershko C., Pinson A., Link G. Prevention of anthracycline cardiotoxicity by iron chelation // Acta Haematol. 1996. — Vol. 95(1). — P. 87 — 92.
- Hierlihy A.M., Seale P., Lobe C.G. et al. The post-natal heart contains a myocardial stem cell population // FEBS Lett. 2002. — Vol. 530. — P. 239 -243.
- Hrelia S., Fiorentini D., Maraldi T. et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardio-myocytes // Biochem Biophys. Acta. 2002. — Vol. 1567. — P. 150 — 156.
- Iarussi D., Indolfi P., Galderisi M., Bossone E. Cardiac toxicity after anthracycline chemotherapy in childhood // Herz. 2000. — Vol. 25, № 7. — P. 676−688.
- Ischiropoulos H. Biological tyrosine nitration: A pathophysiological function of nitric oxide and reactive oxygen species // Arch. Biochem. Biophys. -1998.-Vol. 356.-P. 1−11.
- Ito H., Miller S.C., Billingham M.E. et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro // Proc. Natl. Acad. Sci. USA. 1990. — Vol. 87. — P. 4275 — 4279.
- Jeyaseelan R., Poizat C., Baker R.K. et al. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes // J. Biol. Chem. 1997. — Vol. 272(36). — P. 22 800−22 808.
- Johnson S.A., Richardson D.S. Anthracyclines in haematology: phar-macocinetics and clinical studies // Blood Rev. 1998. — Vol. 12 (1). — P. 52 — 71.
- Jones R.L., Swanton C., Ewer M.S. Anthracycline cardiotoxicity // Expert Opin. Drug. Saf. 2006. — Vol. 5. — P. 791 — 809.
- Kang Y.J., Chen Y., Epstein P. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice // J. Biol. Chem. 1996. — Vol. 271. — P. 12 610- 12 616.
- Kang Y.J., Zhou Z.-X., Wang G.-W., Buridi A., Klein J.B. Supression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases // J. Biol. Chem. 2000. — Vol.275.-P. 13 690 -13 698.
- Keltai K., Cervenak L., Mako V. et al. Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells // Vascul. Pharmacol. 2010. — Vol. 53 (5−6). — P. 209 — 214.
- Kenis Y., Michel J., Rimoldi R. et al. Results of a clinical trial with intermittent doses of adriamycin in lung cancer // Eur. J. Cancer. 1972. — Vol. 8, N5.-P. 485−489.
- Kim Y.D., Lees D.E., Lake C.R. et al. Hyperthermia potentiates doxo-rubicin-related cardiotoxic effects // JAMA. 1979. — Vol. 241. — P. 1816 — 1817.
- Kiyomiya K.-I., Matsuo S., Kurebe M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus // Life Sci. 1998. — Vol. 62.-P. 1853- 1860.
- Kiyomiya K.-L, Matsuo S., Kurebe M. Mechanism of specific nuclear transport of adriamycin: The mode of nuclear translocation of adriamycin-proteasome complex // Cancer Res. 2001. — Vol. 61. — P. 2467 — 2471.
- Kiyomiya K.-I., Satoh J., Horie H. et al. Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome // Int. J. Oncol. 2002. — Vol. 21, № 5. p. 1081 — 1085.
- Konorev E.A., Vanamala S., Kalyanaraman B. Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes // Free Radic. Biol. Med. 2008. — Vol. 45(12). — P. 1723 — 1728.
- Kotamraju S., Konorev E.A.,. Joseph J., Kalyanaraman B. Doxorubi-cin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen // J. Biol. Chem. — 2000. Vol. 275. — P. 33 585 -33 592.
- Kumar D., Kirshenbaum L., Li T. et al. Apoptosis in isolated adultcardiomyocytes exposed to adriamycin // Ann. N.Y. Acad. Sci. 1999. — Vol. 874.-P. 156−168.
- Lakatta E. Cardiovascular regulatory mechanisms in advanced age // Physiol. Rev. 1993. — Vol. 73. -P. 413 -467.
- Lakatta E.G. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging // Circulation. 2003. — Vol. 107, № 3. — P. 490 — 497.
- Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II: The aging heart in health: links to heart disease //Circulation. 2003. — Vol. 107.-P. 346 — 354.
- Lebrecht D., Setzer B., Cetelsen U-P. et: al.. Time-dependent and tissue-specific accumulation of mtDNA. and respiratory chain defects in chronic doxorubicin cardiomyopathy // Circulation. 2003. — Vol. 108. -P.2423- 2429-
- Lebrecht D., Walker U.A. Role of mtDNA lesions in anthracycline ardiotoxicity // Cardiovasc. Toxicol. 2007. — Vol. 7(2). — P. 108?- 113.
- Lee J.Y., Choi Y.S., Suh J.S. et al. Cell penetrating chi-tosan/doxorubicin/TAT conjugates for efficient cancer therapy // Int. J. Cancer -2011. Vol. 128, № 10. — P. 2470 — 2480.
- Lefrak E, A., Pitha j., Rosenheim S., Gottlieb J.A. A clinic-pathologic analysis of adriamycin cardibtoxicity // Cancer. — 1973. — Vol. 32. — P. 302 — 314.
- Legha S.S., Benjamin R.S., Mackay B. et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion // Ann. Intern. Med.- 1982. Vol. 96. — P. 133 — 139.
- Leonard R.C., Williams S., Tulpule A. et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet) // Breast. 2009. — Vol. 18, № 4. — P.218 — 224.
- Levkau B., Schafers M"., Wohlschlaeger J. et al. Survivin determines cardiac function by controlling total cardiomyocyte number // Circulation. 2008. — Vol. 117(12).- P. 1583−1593.
- Lewis W., Kleinerman J., Puszkin S. Interaction of adriamycin in vitro with cardiac myofibrillar proteins // Circ Res. 1982. — Vol. 50(4). — P. 547 -553.
- Li J., Gwilt P.R. The effect of age on the early disposition of doxorubicin // Cancer Chemother. Pharmacol. 2003. — Vol. 51, № 5. — P. 395 — 402.
- Li P., Nijihawan D., Budihardjo I. et al. Cytochrome c and dATP-dependent formation of apaf-l/caspase-9 complex initiations an apoptotic protease cascade // Cell. 1997. — Vol. 91. — P. 479 — 489.
- Li P.Y., Lai P. S., Hung W.C., Syu W.J. Poly (1-lactide) vitamin E NPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells // Biomacromolecules. — 2010. — Vol. 11(10). — P. 2576−2582.
- Li T., Singal P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol // Circulation. 2000. -Vol. 102.-P. 2105−2110.
- Li W., Nie S., Xie M. et al. A major green tea component, (-)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats // J. Agric. Food. Chem. 2010. — Vol. 28.
- Licata S., Saponiero A., Mordente A., Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction // Chem. Res. Toxicol 2000. — Vol. 13. — P.414 — 420.
- Lipshultz S.E., Colan S.D., Gelber R.D. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood // N. Engl. J. Med. 1991. — Vol. 324. — P. 808 — 815.
- Lipshultz S.E., Lipsitz S.R., Mone S. et al. Female sex and higher drug dose as risk factors for late cardiotoxic affects of doxorubicin therapy for childhood cancer // N. Engl. J. Med. 1995. — Vol. 332. — P. 1738 — 1743.
- Lori J.C., Stein T.J., Thamm D.H. Doxorubicin and cyclophosphamidefor the treatment of canine lymphoma: a randomized, placebo-controlled study // Vet. Comp. Oncol. -2010. Vol. 8, № 3. -P.188 — 195.
- Lown J.W. Discovery and development of anthracycline antitumour antibiotics // Chem. Soc. Rev. 1993. — Vol. 22. — P. 165 — 176.
- Lown J.W. Anthracycline and anthraquinone anticancer agents: current status and recent developments // Pharmacol. Ther. 1993. — Vol. 60, № 2. -P.185 -214.
- Lubgun D., Marczak A., Walczak M. Pharmacological mechanisms of doxorubicin activity (DOX) current state of knowledge // Przegl. Lek. — 2006. -Vol. 63, N9.-P. 782−788.
- Madden S.D., Donovan M., Cotter T.G. Key apoptosis regulating proteins are down-regulated during postnatal tissue development // Int. J. Dev. Biol. -2007. Vol. 51 (5). — P. 415 — 423.
- Maejima Y., Adachi S., Ito H., Hirao K., Isobe M. Induction’of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage // Aging Cell. 2008. — Vol. 7(2). — P. 125 — 136.
- Meacham L.R., Chow E.J., Ness K.K. et al Cardiovascular risk factors in adult survivors of pediatric cancer: a report from the childhood cancer survivor study // Cancer Epidemiol. Biomarcers Prev. 2010. — Vol. 19, № 1. — P.170 -181.
- Menna P., Salvatorelli E., Minotti G. Doxorubicin degradation in cardiomyocytes // J. Pharmacol. Exp. Ther. 2007. — Vol. 322, № 1. — P. 408 — 419.
- Mertens A.C. Cause of mortality in 5-year survivors of childhood cancer // Pediatr. Blood. Cancer. 2007. — Vol. 48, № 7. — P.723 — 726.
- Mertens A.C., Yasui Y., Neglia J.P. et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the childhood cancer survivor study//J. Clin. Oncol.-2001.-Vol. 19,№ 13.-P.3163−3172.
- Mhatre R.M., Herman E.H., Waravdekar V.S., Lee I.P. Distribution and metabolism of daunomycin, adriamycin, and N-acetyldaunomycin in the Syrian golden hamster // Biochem. Med. 1972. — Vol. 6, № 5. — P. 445 — 453.
- Mihm M.J., Yu F., Weinstein D.M. et al. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: Evidence for selective impairment of myofibrillar creatine kinase // Br. J. Pharmacol. 2002. — Vol. 135. — P. 581−588.
- Minotti G., Cairo G., Monti E. Role of iron anthracycline cardiotoxici-ty: New tunes for an old song? // FASEB J. 1999. — Vol. 13. — P. 199 — 212
- Minotti G., Recalcati S., Mordente A. et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium // FASEB J. 1998. — Vol. 12. -P. 541 -552.
- Minotti G., Menna P., Salvatorelli E. et al. Anthracyclines: molecular advances and pharmacologic development in antitumor activity and cardiotoxicity // Pharmacol. Rev. 2004. — Vol. 56. — P. 185 — 229.'
- Minow R.A., Benjamin R.S., Lee E.F., Gottlieb J.A. Adriamycin cardiomyopathy risk factors // Cancer. — 1977. — Vol. 39. — P. 1397 — 1402.
- Mordente A., Minotti G., Martorana G.E. et al. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications // Biochem. Pharmacol. 2003. — Vol. 66, № 6. -P.989 — 998.
- Mori Y., Kondo C., Tonomura Y., Torii M., Uehara T. Identificationof potential genomic biomarkers for early detection of chemically induced cardio-toxicity in rats // Toxicology. 2010. — Vol. 271 (1 — 2). — P. 36 — 44.
- Myers C. The role of iron in doxorubicin-induced* cardiomyopathy // Semin. Oncol. 1998. — Vol. 25, 4 Suppl. 10. — P. 10 — 14.
- Nakamura T., Ueda Y., Juan Y. et al. Fas-mediated apoptosis in adri-amycin-induced cardiomyopathy in rats // Circulation. 2000. — Vol. 102. — P. 572 — 578.
- Nithipongvanitch R., Ittarat W., Cole M.P. et al. Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (adriamycin)? // Antioxid. Redox. Signal. 2007. — Vol. 9, № 7. — P. 1001 — 1008.
- Oeffinger K.C., Mertens A.C., Sklar C.A. et al. Chronic health conditions in adult survivors of childhood cancer // New Engl. J. Med. 2006. — Vol. 355, № 15.-P. 1572−1582.
- Ogura R., Sugiyama M., Haramaki N., Hidaka T. Electron spin resonance studies on the mechanism of adriamycin-induced heart mitochondrial damages // Cancer Res. 1991. — Vol. 51. — P. 3555−3558.
- Olson H.M., Young D.M., Prieur D.J., LeRoy A.F., Reagan R.L. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits // Am. J. Pathol. 1974. — Vol. 77. — P. 439 — 454.
- Olson R.D., Gambliel H.A., Vestal R.E. et al. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine // Cardiovasc. Toxicol. 2005. — Vol. 5, № 3. — P.269 — 283.
- Ondrias K., Borgatta L., Kim D: H., Ehrlich B: E. Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle // Circ. Res. 1990. — Vol. 67. — P. 1167 — 1174.
- Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention // Drug Saf. 2000. — Vol. 22. — P. 263 — 302.
- Palmer A., Rivett A.J., Thomson S. et al. Subpopulations of pro-teasomes in rat liver nuclei, microsomes and cytosol // Biochem. J. 1996. — Vol. 316.-P. 401−407.
- Pacher P., Liaudet L., Bai P. et al. Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure // J. Pharmacol. Exp. Ther. 2002. — Vol. 300, № 3. — P. 862 — 867.
- Pacher P., Liaudet L.L., Bai P., Mabley J.G. et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction // Circulation. 2003. — Vol. 107. — P. 896 — 904.
- Papoian T., Lewis W. Adriamycin cardiotoxicity in vivo. Selective alterations in rat cardiac mRNA // Am. J. Pathol. 1990. — Vol. 136. — P. 1201 -1207.
- Peng X., Chen B., Lim C.C., Sawyer D.B. The cardiotoxicology of an-thracyline chemotherapeutics: translating molecular mechanism into preventative medicine // Mol. Interv. 2005. — Vol. 5, № 3. — P. 163 — 171.
- Perego P., Corna E., De Cesare M. et al. Role of apoptosis and apopto-sis-related genes in cellular response and antitumor efficacy of anthracyclines // Curr. Med. Chem. 2001. — Vol. 8. — P. 31 — 37.
- Peters K., Unger R.E., Brunner J., Kirkpatrick C.J. Molecular basis of endothelial dysfunction in sepsis // Cardiovasc. Res. 2003. — Vol. 60 (1). — P. 49 -57.
- Pointon A.V., Walker T.M., Phillips K.M. et al., Doxorubicin in vivo rapidly alters expression and translation of myocardial', electron transport chains genes, lead to ATP loss and caspase 3 activation // PLos. One. 2010. — Vol. 5, № 9. — P. el2733.
- Praga C., Beretta G., Vigo P.L. et al. Adriamycin cardiotoxicity: A survey of 1273 patients // Cancer Treat. Rep. 1979. — Vol. 63. — P. 827 — 834.
- Rabelo E., De Angelis K., Bock P. et al. Baroreflex sensitivity and oxidative stress in adriamycin-induced heart failure // Hypertension. 2001. — Vol. 38, Pt. 2.-P. 576−580.
- Rai K.R., Holland J.F., Glidewell OJ. et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B // Blood. 1981. Vol. 58.-P. 1203−1212.
- Rivett A.J., Palmer A., Knecht E. Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells // J. Histo-chem. Cytochem. 1992. — Vol. 40. — P. 1165 — 1172.
- Rossini L., Monti L., Cova D., Piccinini F. Determination of doxorubicin and doxorubicin-3-ol in rat heart // Arch. Noxicol. 1986. — Suppl. 9. — P. 474−478.
- Saad S.Y., Najjar T.A., Alashari M. Cardiotoxicity of doxorubi-cin/paclitaxel combination in rats: effect of sequence and timing of administration // J. Biochem. Mol. Toxicol. 2004. — Vol. 18. — P. 78 — 86.
- Samaras S. E, Shi Y., Davidson J.M. CARP: fishing for novel mechanisms of neovascularization // J. Investig. Dermatol. Symp. Proc. 2006. — Vol. 11(1).-P. 124−131.
- Sanchis D., Mayorga M., Ballester M., Cornelia JLX. Lack of Apaf-1 expression confers resistance to cytochrome c-driven apoptosis in cardiomyocytes // Cell. Death. Differ. 2003. — Vol. 10(9). — P. 977 — 986.
- Santos R.V. Caperuto E.C. Mello M.T., Rosa L.F. Effect of doxorubicin on cytokine production by lymphocytes and the Thl/Th2 balance // Biomed. Pharmacother. 2010
- Shapira J., Gotfried M., Lishner M., Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: A prospective randomized evaluation // Cancer. 1990. — Vol. 65. — P. 870 — 873.
- Shioji K., Kishimoto C., Nakamura H. et al. Overexpression of thiore-doxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity // Circulation. 2002. — Vol. 106 — P. 1403 — 1409.
- Simpson C., Herr H., Courville K.A. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy // Clin. J. Oncol. Nurs. 2004. -Vol. 8, № 5. — P.497 — 501.
- Simunek T., Sterba M., Popelova O. et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron // Pharmacological Reports. 2009. — Vol. 61. — P:154 — 171.
- Singal P.K., Deally C.M., Weinberg L.E. Subcellular effects- of adri-amycin in the heart: a concise review // J. Mol. Cell. Cardiol. 1987. — Vol. 19. -P. 817−828.
- Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy // N. Engl. J. Med. 1998. — Vol. 339. — P. 900 — 905.
- Singh A.K., Manns M.P., Seidler U. Cytoprotective effects of acidosis via heat shock protein against the anticancer drug doxorubicin // Cell. Mol. Life. Sci. -2010.
- Siveski-Iliskovic N., Hill M., Chow D.A., Singal P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect // Circulation. 1995. — Vol. 91. — P. 10 — 15.
- Smith L.A., Cornelius V.R., Plummer C.J. et al. Cardiotoxicity of an-thracycline agents for the treatment of cancer: systematic review and metaanalysis of randomized controlled trials // BMC Cancer. 2010. — Vol. 29, № 10. -P. 337.
- Steinberg J.S., Cohen A.J., Wasserman A.G. et al. Acute a rhythmo-genicity of doxorubicin administration // Cancer. 1987. — Vol. 60. — P. 1213 -1218.
- Steinherz L.J., Steinherz P.G., Tan C.T. et al. Cardiac toxicicty 4 to 20 years after completing anthracycline therapy // JAMA. 1991. — Vol. 266. — P. 1672−1677.
- Sun X., Zhou Z., Kang Y.J. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart // Cancer Res. -2001.-Vol. 61.-P. 3382−3387.
- Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials // Cancer. -2003. Vol. 97, № 11. — p. 2869 — 2879.
- Swynghedauw B. Molecular mechanisms of myocardial remodeling // Physiol. Rev. 1999. — Vol. 79. — P. 215 — 262.
- Swystun L.L., Shin L.Y., Beaudin S., Liaw P.C. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes // J. Thromb. Haemost. 2009. — Vol. 7(4). — P. 619−626.
- Takase B., Uehata A., Akima T. et al. Endothelium-dependent flowmediated vasodilatation in coronary and brachial arteries in suspected coronary artery disease // Am. J. Cardiol. 1998. — Vol. 82 (12). — P. 1535 — 1539.
- Tafani M., Schneider T.G., Pastorino J.G., Farber J.L. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition // Am. J. Pathol. 2000. — Vol. 156. — P. 2111−2121.
- Thorburn A., Frankel A.E. Apoptosis and anthracycline cardiotoxicity // Mol. Cancer Ther. 2006. — Vol. 5, P. 197 — 199.
- Tian R.H., Zhang Yan C.H., Dai Y.R. Involvement of poly (ADP-ribose) polymerase and activation of caspase-3-like protease in heat shock-induced apoptosis in tobacco suspension cells // FEBS Lett. 2000. — Vol. 474. -P. 11−15.
- Todorova V.K., Kaufmann Y., Hennings L., Klimberg V.S. Oral glu-tamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats // J. Nutr. 2010. — Vol. 140, № l. — P.44 — 48.
- Tokarska-Schlattner M., Zaugg M., Zuppenger C. et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics // J. Mol. Cell". Cardiol. 2006. — Vol. 41, № 3. — P. 389 — 405.
- Torella D., Rota M., Nurzynska D. et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression // Circ. Res. 2004. — Vol. 94. — P. 514 — 524.
- Turko I., Murad F. Protein nitration in cardiovascular diseases // Pharmacol. Rev. 2002. — Vol. 54. — P. 619 — 634.
- Van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients // Cochrane Database Syst. Rev. 2010. — Vol. 5. — P. CD005006.
- Van der Pal H.J., van Dalen E.C., Hauptmann M. et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study // Arch. Intern. Med.-2010.-Vol. 170, N14.-P. 1247- 1255.
- Vargas-Munar D.S., Sarria-Perea J.A., Duarte J.M. Different responses to doxorubicin-induced chromosome aberration in Brazilian deer species // Genet. Mol. Res. 2010. — Vol. 9, № 3. — P. 1545 — 1549.
- Vejlstrup N.G., Bouloumie A., Boesgaard S. et al. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure // J. Mol. Cell. Cardiol. 1998. — Vol. 30. — P. 1215 — 1223.
- Von Hoff D.D., Rozencweig M., Layard M., Slavik M., Muggia F.M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases // Am. J. Med. 1977. — Vol. 62(2). — P. 200 — 208.
- Wang G.-W., Klein J.B., Kang Y.J. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in car-diomyocytes // J. Pharmacol. Exp. Ther. 2001. — Vol. 298. — P. 461 — 468.
- Weinstein D.M., Mihm M.J., Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice // J. Pharmacol. Exp. Ther. 2000. — Vol. 294. — P. 396 — 401.
- Wolf M.B., Baynes J.W. The anti-cancer drug, doxorubicin, causes oxidant, stress-induced endothelial dysfunction // Biochim. Biophys. Acta. 2006. -Vol. 1760(2).-P. 267−271.
- Wosilait W.D., Ryan M.P. Drug interactions affecting the elimination of doxorubicin in the rat // Res. Commun. Chem. Pathol. Pharmacol. 1987. -Vol. 56, № 3.-P. 335−348.
- Yamag D., Elmas C., Ozogul C., Keskil Z., Dursun A. Ultrastructural damage in vascular endothelium in rats treated with paclitaxel and doxorubicin // Ultrastruct. Pathol. 2006.-Vol. 30(1).-P. 103−110.
- Yamaoka M., Yamaguchi S., Suzuki T., Okuyama M. et al. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with-doxorubicin // J. Mol. Cell. Cardiol. 2000. — Vol. 32. — P. 881 — 889.
- Yarmolenko P. S., Zhao Y., Landon C. et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours // Int. J. Hyperthermia. 2010. — Vol. 26, № 5. — P.485 -498.
- Zhang Y.W., Shi J., Li Y.J., Wei L. Cardiomyocyte death in doxorubi-cin-induced cardiotoxicity // Arch. Immunol. Ther. Exp. 2009. — Vol. 57, № 6. -P.435 -445.
- Zhou S., Palmeira C.M., Wallace K.B. Doxorubicin-induced persistent oxidative stress to cardiac myocytes // Toxicol. Lett. 2001. — Vol. 121. — P. 151 -157.
- Zhu W., Shou W., Payne R.M., Caldwell R., Field L J. A mouse model: for juvenile doxorubicin-induced cardiac dysfunction // Pediatr Res. -2008. Vol. 64(5). — P. 488 — 494.
- Zhu W., Zou Y., Aikawa R. et al. MAPK superfamily plays an important role, in daunomycin-induced apoptosis of cardiac myocytes // Circulation: -1999.-Vol. 100.-P. 2100−2107.
- Zima T., Tesar V., Mantle D. et al. Acute doxorubicin (adriamycin) Dosage does not reduce cardiac protein synthesis in vivo, but decreases dia-minopeptidasa I and proline endopeptidase activities // Exp. Mol. Pathol. 2001. -Vol. 70. — P. 154−161.
- Zunino F., Gambetta R., Di Marco A., Zaccara A. Interaction of daunomycin and its derivatives with DNA // Biochim. Biophys. Acta. 1972. -Vol. 277.-P. 489−498.
- Zunino F., Pratesi G., Perego P. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccha-ride analogs//Biochem. Pharmacol.-2001.-Vol. 61.-P. 933−938.